Darifenacin, Solifenacin Urinary Incontinence Drugs Could Hit Market In 2003
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The urinary incontinence market could see the entry of two significant competitors in 2003, with recent NDA submissions for Pfizer’s darifenacin and Yamanouchi’s solifenacin (YM-905).You may also be interested in...
Indevus Sanctura Comparative Claims Not Supported By NDA, FDA Finds
NME "Approvables" Outnumber Approvals Six To Two In October
Market Analysis From Decision Resources
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: